Welcome : Guest

Mast Therapeutics, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Mast Therapeutics, Inc., which is principally a Clinical-Stage Biopharmaceutical Company. Illustrated with 25 tables, the report showcases the company's recent news stories and events, key markets and market position as against its competitors operating in the industry.

Code: PCP-64849
Price: $1250
Company Type: Public
Pages: 28
Date: January 2016
Market Data Tables: 25

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Biopharmaceuticals......3
Table 1: Biopharmaceuticals Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for Asia, Africa and Australia, Europe, US and Others......3
Biologics......4
Table 2: Biological Drugs Market by Product Segment Worldwide (2015) - Percentage Share Breakdown by Value for Daratumuma, Elotuzumab, MOR202 and SAR650984......4
Table 3: Dermatology Biologics Market by Product Type Worldwide (2014) - Percentage Share Breakdown by Value Sales for ENBREL, HUMIRA, REMICADE, and STELARA......5
Table 4: Injectables Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Biologics, Standard Injectables, Vaccines and Others......6
Table 5: No. of Biologics in Development by Therapeutic Area Worldwide (2014) - Percentage Market Share Breakdown for Autoimmune Disorders, Blood Disorders, Cancer/ Related Conditions, Cardiovascular Disease, Diabetes/Related Conditions, Digestive Disorders, Eye Conditions, Genetic Disorders, Infectious Diseases, Musculoskeletal Disorders, Neurologic Disorders, Respiratory Disorders, Skin Diseases, Transplantation, and Others......7
Table 6: Therapeutic Biologics Market by Type in China (2014) - Percentage Share Breakdown by Value for Erythropoietin (EPO), Granulocyte Colony-Stimulating Factor (GCSF), Insulin, Interferon, Interleukin, Monoclonal Antibodies (MAb), Nerve GF, Somatropin, and Others......8
Table 7: Injectable Products Market by Type in Europe (2014) - Percentage Breakdown by Value Sales for Biologics, Biosimilars, Branded Injectables and Generic Injectables......9
Table 8: Biologics Therapeutic Classes Market by Category in China (2014) - Percentage Share Breakdown by Value for Cardiovascular, CNS, Dermatology, Hematology, Metabolic, Musculoskeletal, Oncology, Urinary, and Others......10
Biosimilars......11
Table 9: Biosimilars Market by Segment Worldwide (2014) - Percentage Share Breakdown by Value for Erythropoietin (EPO), Filgrastim, New Biosimilars, and Somatropin......11
Pulmonary Arterial Hypertension (PAH)......12
Table 10: Peripheral Arterial Disease Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Amputation, Bypass, Endovascular, Medical Management, and Non Treatment......12
Table 11: Pulmonary Arterial Hypertension (PAH) Treatment by Drug Worldwide (2014) - Percentage Market Share Breakdown by Value Sales for Adcirca, Letairis/Volibris, Remodulin, Revatio, Tracleer, Tyvaso and Ventavis......13
Table 12: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy Worldwide (2014) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......14
Table 13: Pulmonary Arterial Hypertension (PAH) Treatment with Macitentan Drug by Region Worldwide (2014) - Percentage Market Share Breakdown by Value for Japan, US and Rest of World......15
Table 14: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type Worldwide (2014) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......16
Table 15: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy in Europe (2014) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......17
Table 16: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type in Europe (2014) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......18
Table 17: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy in the US (2014) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......19
Table 18: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type in the US (2014) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......20
Table 19: Pulmonary Arterial Hypertension Treatment Market by Product Segment in Japan (2015) - Percentage Share Breakdown by Value for Adcirca, Dorner, Flolan, Procylin, Revatio, and Tracleer......21
Biopharmaceuticals......22
Table 20: Market Shares of Leading Biopharmaceutical Companies Worldwide (2014) - Percentage Breakdown by Volume (Installed Capacity) for Amgen Inc., Biogen Idec, Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Ltd., Lonza Group Ltd., Pfizer, Inc., Sanofi S.A., and Others......22
Table 21: Market Shares of Leading Hemophilia Medicine Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Baxter International, Inc., Bayer AG, CSL Limited, Grifols, S.A., Kedrion S.p.A, Novo Nordisk A/S, Octapharma AG, and Pfizer, Inc.......23
Table 22: Market Shares of Leading Immunohematology Product Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Bio-Rad Laboratories, Inc., Grifols, S.A., Immucor, Inc., Ortho Clinical Diagnostics, and Others......24
Table 23: Market Shares of Leading Nerve Growth Factor (NGF) Companies in China (2014) - Percentage Share Breakdown by Value for Ningbo Hi-Tech Biochemicals Co., Ltd., Staidson (Beijing) Biopharmaceuticals Co., Ltd., Xiamen Bioway Pku Co., Ltd., and Others......25
Table 24: Market Shares of Leading Pulmonary/ Alpha-1 Proteinase Inhibitor (A1PI) Providers in the US (2015) - Percentage Breakdown by Value for Baxter International Inc., CSL Limited, and Grifols, S.A.......26
Speciality Pharmaceuticals......27
Table 25: Speciality Pharmaceuticals Market by Category in the US (2014) - Percentage Share Breakdown by Value Sales for Anti-Coagulant, Growth Hormone, Hepatitis C, HIV/AIDS (incl oral solids), IVIG/Hemophilia, Macular Degeneration, Multiple Sclerosis, Oncology (incl. oral solids), Pulmonary Arterial Hypertension, Renal, Rheumatoid arthritis/Chrohn's, Transplant, and Others......27